Adherex Technologies (FENC)
(Delayed Data from NSDQ)
$5.24 USD
-0.05 (-0.95%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.25 +0.01 (0.19%) 7:58 PM ET
5-Strong Sell of 5 5
D Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FENC 5.24 -0.05(-0.95%)
Will FENC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FENC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FENC
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
Fortrea Holdings Inc. (FTRE) Reports Q2 Loss, Lags Revenue Estimates
FENC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
Implied Volatility Surging for Fennec (FENC) Stock Options
Other News for FENC
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
Fennec price target lowered by $2 at H.C. Wainwright, here's why
Fennec price target lowered by $2 at Craig-Hallum, here's why
Buy Rating for Fennec Pharmaceuticals Bolstered by Pedmark’s Market Expansion and New Leadership
Fennec Pharmaceuticals Inc (FENC) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue ...